Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mary G, Quinn"'
The inhibition of poly(ADP-ribose) polymerase (PARP) enzymes is a relatively new anticancer therapeutic strategy designed to impair the ability of tumor cells to repair DNA damage. PARP inhibitors induce synthetic lethality in cells lacking the abili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e2e8d2e934e804f33f8f00bbe7b2f08
https://doi.org/10.1016/b978-0-12-813753-6.00011-1
https://doi.org/10.1016/b978-0-12-813753-6.00011-1
Autor:
John Crown, Jessica-Clare Long, Susan Cairney, D. McDonnell, John M. Gannon, Conor Buckley, Aileen O'Meara, J. Ballot, Janice M. Walshe, David Fennelly, Mary G. Quinn, Therese Lyons, Giuseppe Gullo
Publikováno v:
Journal of Clinical Oncology. 36:e12522-e12522
e12522Background: Taxane-containing Adj is an accepted life-prolonging component of modern multi-modal ESB therapy. One of the most distressing complications of Adj is alopecia. While patients (pts...
Autor:
Larry Rubinstein, Naoko Takebe, Khanh Tu Do, Howard Streicher, Mary G. Quinn, Robert S. Meehan, Jennifer Zlott, Alice P. Chen, James H. Doroshow, Chana Levine, Shivaani Kummar, Lamin Juwara, Geraldine O'Sullivan Coyne, Richard Piekarz, Elad Sharon
Publikováno v:
Molecular Cancer Therapeutics. 17:B079-B079
Background: Modulation of BRCA1 and ATR has been postulated as an activation mechanism of checkpoint 1 (Chk1), which in turn triggers homologous recombination repair through modulation of BRCA2-Rad51, and the initiation of cell cycle checkpoints thro
Autor:
Dat Nguyen, Barbara Schuler, Nancy Harold, Geraldine Morrison, Xaiodu Guo, Maurice A. Wright, Mary G. Quinn, Jorge P. Leguizamo, Janet Pang, Eva Szabo, Gregory D. Leonard, M. Wasif Saif, Suzanne Fioravanti, Brian P. Monahan, Jon L. Hopkins, Pengxin Lin, Jean L. Grem
Publikováno v:
Clinical Cancer Research. 11:4144-4150
Purpose: In preclinical studies, sequential exposure to irinotecan (CPT-11) then fluorouracil (5-FU) is superior to concurrent exposure or the reverse sequence; a 24-hour infusion of CPT-11 may be better tolerated than shorter infusions. Experimental
Autor:
Chris H. Takimoto, Dat Nguyen, Alice P. Chen, J. Michael Hamilton, Brian P. Monahan, Janet Pang, Mary G. Quinn, Yan Xu, Jean L. Grem, Anthony Rowedder, Bruce Keith, Nancy Harold, Geraldine Morrison
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:487-496
Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial.Gemcitabine alone was given in cycle 1 as a 24
Autor:
Jorge P. Leguizamo, Jean L. Grem, Chris H. Takimoto, Abdel Salam Attia Ismail, Janet Pang, Mary G. Quinn, Michael D. Liang, William L. Dahut
Publikováno v:
Cancer Chemotherapy and Pharmacology. 52:333-338
A phase I pharmacologic study was undertaken to determine the maximum tolerated dose (MTD), to characterize the pharmacokinetic profile, and to evaluate all toxicities of the aqueous colloidal dispersion formulation of 9-aminocampothecin (9-AC).9-AC
Publikováno v:
Oncology Issues. 15:23-27
(2000). The Use of Complementary and Alternative Medicine in Prostate Cancer Patients. Oncology Issues: Vol. 15, No. 6, pp. 23-27.
Publikováno v:
Anti-Cancer Drugs. 15:733-735
Oxaliplatin-based combination chemotherapy is an option for first-line therapy of metastatic colorectal cancer. It is associated with acute hyperexcitability of motor and sensory nerves, and a cumulative sensory axonal neuropathy. We describe a 56-ye
Autor:
Barbara Schuler, Jean L. Grem, Rebecca R. Thomas, Maurice A. Wright, Suzanne Fioravanti, Mary G. Quinn, Gregory D. Leonard, Nancy Harold
Publikováno v:
BMC Cancer, Vol 5, Iss 1, p 116 (2005)
BMC Cancer
BMC Cancer
Background New chemotherapy regimens for patients with colorectal cancer have improved survival, but at the cost of clinical toxicity. Oxaliplatin, an agent used in first-line therapy for metastatic colorectal cancer, causes acute and chronic neuroto
Autor:
Jean L. Grem, Aaron Ernst, Maurice A. Wright, Vivian Kao, Ilan R. Kirsch, Allison Parr, Liam Grogan, Abdel Salam Attia Ismail, Frank Grollman, Mary G. Quinn
Publikováno v:
Oncology Reports.
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon alpha-2a (IFN-alpha). This phase II study assessed